1. Home
  2. LNSR vs SPRO Comparison

LNSR vs SPRO Comparison

Compare LNSR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$4.49

Market Cap

71.7M

Sector

Health Care

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$0.74

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNSR
SPRO
Founded
2004
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Electronics
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.7M
67.0M
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
LNSR
SPRO
Price
$4.49
$0.74
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
★ $11.00
$5.33
AVG Volume (30 Days)
68.0K
★ 333.8K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.81
EPS
★ 0.56
N/A
Revenue
$58,435,000.00
★ $66,802,000.00
Revenue This Year
$4.22
N/A
Revenue Next Year
$19.43
N/A
P/E Ratio
$8.38
★ N/A
Revenue Growth
9.24
★ 39.24
52 Week Low
$4.30
$0.81
52 Week High
$12.94
$3.08

Technical Indicators

Market Signals
Indicator
LNSR
SPRO
Relative Strength Index (RSI) 29.73 24.11
Support Level $4.30 N/A
Resistance Level $6.29 $1.27
Average True Range (ATR) 0.40 0.07
MACD -0.03 -0.02
Stochastic Oscillator 9.12 1.76

Price Performance

Historical Comparison
LNSR
SPRO

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: